RESEARCH GRANT AWARDS
AWARDS LIST.
Totals by Year
2022 - $1,199,966
2021 - $749,812
2020 - $630,000
2019 - $690,000
2018 - $750,000
2017 - $747,772
2016 - $720,000
2015 - $840,000
2014 - $810,000
2013 - $808,500
2012 - $720,000
2011 - $599,780
2010 - $438,000
2009 - $435,000
2008 - $619,993
2007 - $232,600
2006 - $384,551
John Tentler, PhD
2022
$30,000
Cancer Research Summer Fellowship Program
Michelle Williams, PhD
2022
$30,000
Targeting Heme Metabolism to Enhance Sensitivity to Immunotherapy in Metastatic Triple-Negative Breast Cancer
Jung-Jae Lee, PhD
2022
$ 30,000
Body heat activated storable, near-infrared, self-illuminating nanoprobes for in vivo optical imaging of cancer
Camille Stewart, MD and Mayumi Fujita, MD, PhD
2022
$59,969
Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
Matthew Witkowski, PhD
2022
$30,000
Targeting RNA-binding protein, NUDT21, enhances CD19 abundance on human B-cell acute lymphoblastic leukemia cells
Joshua Black, PhD and Heide Ford, PhD
2022
$60,000
Assessing the Prevalence of DNA Rereplication During Epithelial to Mesenchymal Transition in Breast Cancer
Martin Barrio, MD, MS
2022
$30,000
Identifying clinical and genetic features associated with thyroid cancer risk of recurrence
Jessica Floyd, MD
2022
$30,000
Modulation of the immune suppressed tumor microenvironment in high grade serous ovarian cancer through interventions in the tryptophan catabolism pathway
Takamitsua Kato, PhD
2022
$30,000
Investigation of mechanisms and feasibility for chemo/radio-sensitization for cancer therapy by SQAP
Nicholas Foreman, MD
2022
$ 30,000
Integration of single-nuclei RNA-sequencing and spatial transcriptomics to study the transformation of highly aggressive malignant peripheral nerve sheath tumors
Tejas Patil, MD and Lynn Heasley, PhD
2022
$60,000
Programmed death receptor (PD-L1) expression as a biomarker for tyrosine kinase inhibitor (TKI) efficacy among patients with ALK-rearranged NSCLC
Sujatha Venkataraman, PhD and Eric Kohler, MD, PhD and Masanori Hayashi, MD
2022
$60,000
Pre-clinical evaluation of "SMART CAR"-T cell therapy against primary and metastatic Ewing sarcoma
Khosbayar Lkhagvadorj, PhD
2022
$30,000
An ex-vivo organoid model to identify markers of lung adenocarcinoma premalignancy
Molishree Joshi, PhD, Scott Cramer, PhD, and James Costello, PhD
2022
$60,000
Vitamin D synthetic lethal network across benign and metastatic cell lines
Paul Jedlicka, MD, PhD
2022
$ 30,000
Understanding new mechanisms cooperating with the PAX3/FOX01 driver oncofusion in rhabdomyosarcoma
Douglas H. Thamm, VMD, DACVIM
2022
$29,997
Antitumor and Antimetastatic Effects of MYC Depletion with Omacetaxine in Osteosarcoma
Robert Meguid, MD, PhD, and Christina Stewart, MD
2022
$30,000
Pilot Development of an Enriched Cancer Database using Machine Learning Techniques
Eric T. Clambey, PhD and Raphael A. Nemenoff, PhD
2022
$60,000
Role of Cancer-cell specific MHC II in regulating response to immune checkpoint inhibitors in lung cancer
Yiqun Shellman, PhD and Richard Tobin, PhD
2022
$60,000
Investigating the role of host Sash 1 expression in antitumor Immunity
Nathan Dahl, MD and Rajeev Vibhakar, MD, PhD, MPH
2022
$60,000
CDK9 as a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
Zdenek Andrysik, PhD
2022
$ 30,000
Pre-clinical test of colorectal cancer therapy based on combinatorial activation of p53 and Integrated Stress Response
Todd Pits, PhD, and Julie Lang, PhD
2022
$60,000
Anti-TIGIT antibody in combination with bevacizumab/DC101 and pembrolizumab in microsatellite stable colorectal cancer
Mohamed Ghoneim, PhD
2022
$30,000
Mechanisms of PBAF Remodeling Complex and Effect of Cancer Mutations
Keara Boss, DVM, PhD and Steven Dow, DVM, PhD
2022
$60,000
Establishing a novel orthotopic sinonasal carcinoma model in immunocompetent rats for translational radiation and immunotherapy research
Reema Wahdan, PhD and Daniel LaBarbera, PhD
2022
$60,000
Targeting Thyroid Hormone-Mediated Cancer Stem Cell Expansion and Treatment Resistance in ER+ Breast Cancer cells
Joselyn Cruz Cruz, PhD
2022
$ 30,000
Reversing Immunosuppression in Rhabdomyosarcoma
Jeffrey Moore, PhD
2022
$30,000
Mechanism of Chemotherapeutic Resistance by TUBB3 Tubulin
Shi-Long Lu, MD, PhD and Daniel Frank, PhD
2022
$60,000
Functional assessment of human microbiome in head and neck cancer mouse models
Takeshi Yamauchi, PhD
2021
$30,000
Non-UV risk factors of melanoma
Siddhartha Mitra, PhD
2021
$30,000
Development of Chimeric Antigen Receptor Expressing macrophages and microglia to target pediatric glioblastoma
Rajeev Vibhakar, MD, PhD, MPH
2021
$30,000
Role of BMI1 in SMARB1 deleted ATRTs
Masanori Hayashi, MD
2021
$30,000
Preclinical Investigation of BCOR rearranged solid tumors
Matthew J. Sikora, PhD
2021
$30,000
Targeting an unexplored DNA repair deficiency and radiosensitivity in lobular breast cancer
Carol Sartorius, PhD
2021
$30,000
Lipodependence of endocrine resistant breast cancer as a therapeutic target
John Tentler, PhD
2021
$30,000
Cancer Research Summer Fellowship Program
Satyanarayan Rao, PhD
2021
$30,000
Using transcription factors to map tumor state and microenvironment
Jennifer Matsuda, PhD and James Scott-Browne, PhD
2021
$60,000
Genetic manipulation of human T cell transcriptional programs to improve cancer immunotherapy
Leonora Slatnick, MD
2021
$30,000
Biomarker Development for Sepsis in Pediatric Oncology Patients
Carlo Marchetti, PhD and Mayumi Fujita, MD, PhD
2021
$60,000
Identifying the role of NLRP3 in immunotherapy resistant melanomas
Andrew Getahun, PhD and John Cambier, PhD
2021
$60,000
Identification of novel inhibitory checkpoint receptors
Adam Green, MD and Natalie Serkova, PhD and Mark Borden, PhD
2021
$60,000
MRI-Guided Focused Ultrasound to Improve Treatment of DIPG
Sujatha Venkataraman, PhD
2021
$30,000
Novel CAR T cell therapies to target metastatic Ewing Sarcoma
Paul Jedlicka, MD, PhD
2021
$30,000
Understanding the metastasis-promoting cistrome in Ewing Sarcoma
Santos Franco, PhD, Siddhartha Mitra, PhD and Adam Green, MD
2021
$60,000
Development of In utero driven Mouse Models of Diffused Midline Gliomas to study the tumor immune interactions in Pediatric Midline Gliomas
Elizabeth Kessler, MD
2021
$29,812
Validation of a patient-reported tool to screen for geriatric impairments predictive of potential frailty in cancer patients
Alisa Lee-Sherick, MD and C. Wyatt Shields, PhD
2021
$60,000
Assessment of Cell Types for Delivering MerTK Inhibitors to Sarcomas
Nathan Dahl, MD
2021
$30,000
Unlocking the combination: Potentiation of radiation-induced antitumor effect using clinically-relevant BH3 mimetics to effectively target DIPG
Paula Jedlicka, MD, PhD
2020
$ 30,000
Understanding and targeting highly metastatic EWS/FLi1-low cells in Ewing Sarcoma
Ryan Marker, PhD
2020
$ 30,000
Feasibility and effectiveness of an Innovative exercise program to reduce fatigue in rural cancer survivors
Zdenek Andrysik PhD
2020
$ 30,000
Exploring strong synergism of targeted p53 activation and translation inhibition in colorectal cancer.
Senthilnath Lakshmana Chetty, PhD
2020
$ 30,000
Combining radiation and Immunotherapy to target diffuse midline gliomas with the H3K27M mutation
Breelyn Wilky, MD & Eduardo Davila, PhD
2020
$ 60,000
Toxicity and Biodistribution of CD*:MyD88 Engineered Autologous T Cells In Mouse Models of Melanoma and Fibrosarcoma
Zachary Graff, MD
2020
$ 30,000
Development of Bispecific CAR T-cells for the Prevention of Lineage Switch in KMT2A-rearranged Leukemia
Swati G. Patel, MD, MS
2020
$ 30,000
Identification of Hereditary Cancer Syndromes through Advanced Polyps
Molishree Joshi, PhD
2020
$ 30,000
A novel CRISPR-mediated tumor targeting strategy for Liiposarcoma
Matthew Tallaferro, PhD
2020
$ 30,000
Control of cell division through centrosomal RNA localization
Diana M. Cittelly, PhD
2020
$ 30,000
Function of Ephrin B Signaling in Breast cancer brain metastasis
Rebecca Schweppe, PhD
2020
$ 30,000
The role of Nuclear FAK in Thyroid Cancer
Maureen Lynch, Phd & Philip Owens, PhD
2020
$ 60,000
The role of exercise in breast cancer bone metastasis
Christine Towers, PhD
2020
$ 30,000
Identifying novel regulators of mitochondrial turn over
Sujatha Venkataraman PhD & Adam Green, MD & Mark Kohler, MD, PhD
2020
$ 60,000
Engineering Logic-Gated DC99 CAR to selectively target H3K27M-DIPG tumor cells and to protect normal cells
Mayumi Fujita, MD, PhD & Charles A. Dinarello, MD
2020
$ 60,000
The role of alpha-1 antitrypsin in cancer immunotherapy
Raphael Nemenoff, PhD & Erin Schenk, MD, PhD
2020
$ 60,000
The Tumor Microenvironment as a Critical Regulator of Targeted Therapy in ALK Positive Lung Cancer
Heather Brechbuhl, PhD
2019
$ 30,000
Defining reversible tumor traits in the obese microenvironment
Carol Sartorius, PhD
2019
$ 30,000
PR-RAR downregulation of protein synthesis and cell growth in breast cancer
Cem Altunbas, PhD
2019
$ 30,000
High-fidelity volumetric imaging for quantitative treatment monitoring and modifications in radiation therapy
Isabel Schlaepfer, PhD
2019
$ 30,000
Role of fat oxidation via CPT1A in immunological response to prostate cancer
Paul Norman, PhD
2019
$ 30,000
Natural Killer cells can protect from developing leukemia
Zachary Levi Watson, PhD
2019
$ 30,000
Targeting histone acetylation in PARP inhibitor-resistant ovarian cancer
John Tentler, PhD
2019
$ 30,000
Cancer Research Summer Fellowship Program
Adam Mueller, MD, PhD
2019
$ 30,000
Investigating crosstalk between ADAM10 and EphrinB2/EPHB4 in mediating radiation induced fibrosis, invasion and metastasis in pancreatic cancer
Jay Hesselberth, PhD
2019
$ 30,000
Single-cell methods to measure functional heterogeneity
Sujatha Venkataraman, PhD and Mark Kohler, MD, PhD
2019
$ 60,000
CD99 targeting CAR T cells as a novel therapy for H3K27M mutant DIPG
Shi-Long Lu, MD, PhD and Daniel Frank, PhD
2019
$ 60,000
Mechanism of oral microbiota in head and neck cancer pathogenesis and application for targeted therapy
Yiqun Shellman, PhD & Martin McCarter, MD
2019
$ 60,000
Targeting anti-apoptotic pathways to improve immunotherapies for melanoma